oxiracetam has been researched along with Cognitive Decline in 9 studies
oxiracetam: structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "S-oxiracetam (S-ORC), a nootropic drug, was used to protect against ischemic stroke by lessening the blood brain barrier dysfunction and inhibiting neuronal apoptosis." | 8.02 | S-oxiracetam Facilitates Cognitive Restoration after Ischemic Stroke by Activating α7nAChR and the PI3K-Mediated Pathway. ( Fan, W; Li, X; Xu, C; Zhang, Y, 2021) |
| "Oxiracetam may have a modest effect on preventing cognitive decline." | 5.69 | Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial. ( Bae, HJ; Cha, JK; Chang, DI; Cho, HJ; Cho, KH; Choi, JC; Chung, JW; Heo, JH; Heo, SH; Jung, KH; Kang, Y; Kim, C; Kim, DE; Kim, EG; Kim, HY; Kim, JG; Kim, YI; Kwon, JH; Lee, J; Lee, JH; Lee, KB; Lee, SJ; Lee, YB; Lee, YS; Lim, JS; Moon, WJ; Oh, KM; Oh, MS; Park, H; Park, HT; Park, JH; Park, JM; Park, JW; Park, KY; Park, MS; Park, TH; Rha, JH; Sung, SM; Yi, S, 2023) |
| " The clinical efficacy of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment after stroke was analyzed." | 5.34 | Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment. ( Ma, Z; Qiao, P; Wang, B; Zhong, L, 2020) |
| "S-oxiracetam (S-ORC), a nootropic drug, was used to protect against ischemic stroke by lessening the blood brain barrier dysfunction and inhibiting neuronal apoptosis." | 4.02 | S-oxiracetam Facilitates Cognitive Restoration after Ischemic Stroke by Activating α7nAChR and the PI3K-Mediated Pathway. ( Fan, W; Li, X; Xu, C; Zhang, Y, 2021) |
| " Both Oxiracetam and FNS can reduce cognitive decline post arrival at high altitude." | 3.85 | Oxiracetam or fastigial nucleus stimulation reduces cognitive injury at high altitude. ( Fang, L; Feng, H; Hu, S; Li, W; Shi, J; Xiong, W, 2017) |
| "The in vitro study used a cell injury controller to damage SH-SY5Y cells and evaluate the effect of oxiracetam at a dosage of 100 nM." | 1.91 | Oxiracetam alleviates anti-inflammatory activity and ameliorates cognitive impairment in the early phase of traumatic brain injury. ( Cho, SM; Choi, H; Han, SW; Hong, EP; Jeon, JP; Jung, H; Kim, JT; Kim, N; Lee, A; Lee, Y; Park, CH; Youn, DH, 2023) |
| "Oxiracetam (ORC) was used as a positive drug in this experiment." | 1.62 | Poria cocos polysaccharide attenuates damage of nervus in Alzheimer's disease rat model induced by D-galactose and aluminum trichloride. ( Jiang, Y; Ling, Y; Zhang, Y; Zhou, C; Zhou, X, 2021) |
| "Oxiracetam (ORC) is a commonly used nootropic drug for improving cognition and memory impairments." | 1.51 | Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis/autophagy-related genes associated with the activation of the Akt/mTOR signaling pathway. ( Dong, Y; Jiang, X; Liu, Z; Lv, P; Qi, Q; Xu, J, 2019) |
| "Oxiracetam is a nootropic drug that is commonly used to treat cognitive deficits of cerebrovascular origins." | 1.46 | (S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. ( Guo, Y; Jiang, H; Li, W; Liu, H; Nie, Z; Pu, X; Sun, Y; Wang, C; Xiong, X; Zhang, K; Zhang, X; Zhao, X, 2017) |
| "Oxiracetam is a nootropic drug that improves clinical outcomes for some central nervous system (CNS) disorders." | 1.43 | Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats. ( Li, L; Nie, L; Yao, XL; Yao, ZH; Zhang, SF, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, JS | 1 |
| Lee, J | 2 |
| Kang, Y | 1 |
| Park, HT | 1 |
| Kim, DE | 1 |
| Cha, JK | 1 |
| Park, TH | 1 |
| Heo, JH | 1 |
| Lee, KB | 1 |
| Park, JM | 1 |
| Oh, MS | 1 |
| Kim, EG | 1 |
| Chang, DI | 1 |
| Heo, SH | 1 |
| Park, MS | 1 |
| Park, H | 1 |
| Yi, S | 1 |
| Lee, YB | 1 |
| Park, KY | 1 |
| Lee, SJ | 1 |
| Kim, JG | 1 |
| Cho, KH | 1 |
| Rha, JH | 1 |
| Kim, YI | 1 |
| Lee, JH | 1 |
| Choi, JC | 1 |
| Oh, KM | 1 |
| Kwon, JH | 1 |
| Kim, C | 1 |
| Park, JH | 1 |
| Jung, KH | 1 |
| Sung, SM | 1 |
| Chung, JW | 1 |
| Lee, YS | 1 |
| Kim, HY | 1 |
| Cho, HJ | 1 |
| Park, JW | 1 |
| Moon, WJ | 1 |
| Bae, HJ | 1 |
| Youn, DH | 1 |
| Han, SW | 1 |
| Kim, JT | 1 |
| Choi, H | 1 |
| Lee, A | 1 |
| Kim, N | 1 |
| Jung, H | 1 |
| Hong, EP | 1 |
| Park, CH | 1 |
| Lee, Y | 1 |
| Cho, SM | 1 |
| Jeon, JP | 1 |
| Xu, J | 1 |
| Qi, Q | 1 |
| Lv, P | 1 |
| Dong, Y | 1 |
| Jiang, X | 1 |
| Liu, Z | 1 |
| Wang, B | 1 |
| Zhong, L | 1 |
| Qiao, P | 1 |
| Ma, Z | 1 |
| Fan, W | 1 |
| Zhang, Y | 2 |
| Li, X | 1 |
| Xu, C | 1 |
| Zhou, X | 1 |
| Jiang, Y | 1 |
| Zhou, C | 1 |
| Ling, Y | 1 |
| Li, W | 2 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Wang, C | 1 |
| Guo, Y | 1 |
| Sun, Y | 1 |
| Zhao, X | 1 |
| Xiong, X | 1 |
| Zhang, X | 1 |
| Zhang, K | 1 |
| Nie, Z | 1 |
| Pu, X | 1 |
| Hu, S | 1 |
| Shi, J | 1 |
| Xiong, W | 1 |
| Fang, L | 1 |
| Feng, H | 1 |
| Yao, XL | 1 |
| Yao, ZH | 1 |
| Li, L | 1 |
| Nie, L | 1 |
| Zhang, SF | 1 |
2 trials available for oxiracetam and Cognitive Decline
| Article | Year |
|---|---|
Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial.
Topics: Cognitive Dysfunction; Double-Blind Method; Humans; Pyrrolidines; Quality of Life; Stroke; Treatment | 2023 |
Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment.
Topics: Adult; Aged; Aged, 80 and over; Cognitive Dysfunction; Drug Therapy, Combination; Female; Humans; Ma | 2020 |
7 other studies available for oxiracetam and Cognitive Decline
| Article | Year |
|---|---|
Oxiracetam alleviates anti-inflammatory activity and ameliorates cognitive impairment in the early phase of traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Caspases; Cognitive Dysfunction; Cyclo | 2023 |
Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis/autophagy-related genes associated with the activation of the Akt/mTOR signaling pathway.
Topics: Animals; Apoptosis; Autophagy; Cognitive Dysfunction; Dementia, Vascular; Disease Models, Animal; Ma | 2019 |
S-oxiracetam Facilitates Cognitive Restoration after Ischemic Stroke by Activating α7nAChR and the PI3K-Mediated Pathway.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; CA1 Region, Hippocampal; Cognitive Dysfunction; Di | 2021 |
Poria cocos polysaccharide attenuates damage of nervus in Alzheimer's disease rat model induced by D-galactose and aluminum trichloride.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Apoptosis; Behavior, Animal; Cognition; Cognitive Dys | 2021 |
(S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Astrocytes; Cerebral Cortex; Cerebrovascular Circulat | 2017 |
Oxiracetam or fastigial nucleus stimulation reduces cognitive injury at high altitude.
Topics: Adult; Altitude; Cerebellar Nuclei; Cognition; Cognitive Dysfunction; Electroencephalography; Evoked | 2017 |
Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats.
Topics: Animals; Cerebrovascular Disorders; Cognitive Dysfunction; Disease Models, Animal; Male; Nootropic A | 2016 |